<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37441081</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-&#x3b1;-accelerated lupus nephritis in mice.</ArticleTitle><Pagination><StartPage>1185727</StartPage><MedlinePgn>1185727</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1185727</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1185727</ELocationID><Abstract><AbstractText>Neutrophils have been implicated in initiating and perpetuating systemic lupus erythematosus and the resultant kidney damage in lupus nephritis (LN) patients, in part through an excessive release of neutrophil serine proteases (NSPs). NSP zymogens are activated by dipeptidyl peptidase 1 (DPP1) during neutrophil maturation and released by mature neutrophils in response to inflammatory stimuli. Thus, a potential strategy to attenuate disease progression in LN would be to inhibit DPP1. We tested whether brensocatib, a highly selective and reversible DPP1 inhibitor, could mitigate LN progression in an interferon-alpha (IFN&#x3b1;)-accelerated NZB/W F1 mouse model. To confirm brensocatib's pharmacodynamic effect on NSPs in this mouse strain, repeated dose studies were conducted for 7 and 14 days in na&#xef;ve NZB/W F1 mice <i>via</i> oral gavage twice a day. Brensocatib at 2 and 20 mg/kg/day achieved a significant reduction in bone marrow NSP activities after 7 days of daily administration. To initiate LN disease progression, the mice were injected with an IFN&#x3b1;-expressing adenovirus. After 2 weeks, three brensocatib doses (or vehicle) were administered for 6 more weeks. Throughout the 8-week study, brensocatib treatment (20 mg/kg/day) significantly reduced the occurrence of severe proteinuria compared to the vehicle control. Brensocatib treatment also entailed a significant reduction in the urine albumin-to-creatinine ratio, indicating decreased kidney damage, as well as a significant reduction in blood urea nitrogen level, suggesting improved renal function. Based on kidney histopathology analysis, brensocatib treatment significantly lowered both the renal tubular protein score and the nephropathy score compared to the vehicle group. A trend towards reduced glomerulonephritis score with brensocatib treatment was also observed. Lastly, brensocatib significantly reduced LN mouse kidney infiltration by various inflammatory cells. In conclusion, these results suggest that brensocatib alters disease progression in LN mice and warrant further evaluation of DPP1 inhibition in LN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Chen, Zhang, LaSala, Basso, Chun, Zhou, McDonald, Perkins and Cipolla.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kuan-Ju</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jimin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaSala</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Donald</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Patrick P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Walter R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cipolla</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Research Department of Insmed Incorporated, Bridgewater, NJ, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>25CG88L0BB</RegistryNumber><NameOfSubstance UI="C000619932">brensocatib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.14.-</RegistryNumber><NameOfSubstance UI="D004152">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004152" MajorTopicYN="N">Dipeptidyl-Peptidases and Tripeptidyl-Peptidases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DPP1 inhibitor</Keyword><Keyword MajorTopicYN="N">brensocatib</Keyword><Keyword MajorTopicYN="N">dipeptidyl peptidase 1 (DPPI)</Keyword><Keyword MajorTopicYN="N">interferon-alpha (IFN&#x3b1;)</Keyword><Keyword MajorTopicYN="N">lupus nephritis (LN)</Keyword><Keyword MajorTopicYN="N">neutrophil serine proteases (NSP)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>All authors were employed by the company Insmed Incorporated at the time of the study conduct and/or preparation of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>13</Day><Hour>15</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37441081</ArticleId><ArticleId IdType="pmc">PMC10333524</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1185727</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers (2016) 2:16039. doi:&#xa0;10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol (2016) 12(12):716&#x2013;30. doi:&#xa0;10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, et al. . Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus (2020) 29(9):1011&#x2013;20. doi:&#xa0;10.1177/0961203320932219</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320932219</ArticleId><ArticleId IdType="pmc">PMC7425376</ArticleId><ArticleId IdType="pubmed">32571142</ArticleId></ArticleIdList></Reference><Reference><Citation>Piga M, Arnaud L. The main challenges in systemic lupus erythematosus: where do we stand? J Clin Med (2021) 10(2). doi:&#xa0;10.3390/jcm10020243</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020243</ArticleId><ArticleId IdType="pmc">PMC7827672</ArticleId><ArticleId IdType="pubmed">33440874</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Chen Y, Wu H, Liao J, Cheng B, Lu Q. Therapeutic advances in the treatment of sle. Int Immunopharmacol (2019) 72:218&#x2013;23. doi:&#xa0;10.1016/j.intimp.2019.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2019.03.010</ArticleId><ArticleId IdType="pubmed">31002998</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers (2020) 6(1):7. doi:&#xa0;10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol (2019) 31(6):682&#x2013;8. doi:&#xa0;10.1097/BOR.0000000000000642</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000642</ArticleId><ArticleId IdType="pmc">PMC6812494</ArticleId><ArticleId IdType="pubmed">31389814</ArticleId></ArticleIdList></Reference><Reference><Citation>Podolska MJ, Biermann MH, Maueroder C, Hahn J, Herrmann M. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflammation Res (2015) 8:161&#x2013;71. doi:&#xa0;10.2147/JIR.S70325</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S70325</ArticleId><ArticleId IdType="pmc">PMC4548750</ArticleId><ArticleId IdType="pubmed">26316795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fresneda Alarcon M, McLaren Z, Wright HL. Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: same foe different m. O. Front Immunol (2021) 12:649693. doi:&#xa0;10.3389/fimmu.2021.649693</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.649693</ArticleId><ArticleId IdType="pmc">PMC7969658</ArticleId><ArticleId IdType="pubmed">33746988</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neil LJ, Kaplan MJ, Carmona-Rivera C. The role of neutrophils and neutrophil extracellular traps in vascular damage in systemic lupus erythematosus. J Clin Med (2019) 8(9). doi:&#xa0;10.3390/jcm8091325</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8091325</ArticleId><ArticleId IdType="pmc">PMC6780421</ArticleId><ArticleId IdType="pubmed">31466329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MJ. Neutrophils in the pathogenesis and manifestations of sle. Nat Rev Rheumatol (2011) 7(12):691&#x2013;9. doi:&#xa0;10.1038/nrrheum.2011.132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2011.132</ArticleId><ArticleId IdType="pmc">PMC3243068</ArticleId><ArticleId IdType="pubmed">21947176</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al. . Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 187(1):538&#x2013;52. doi:&#xa0;10.4049/jimmunol.1100450</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100450</ArticleId><ArticleId IdType="pmc">PMC3119769</ArticleId><ArticleId IdType="pubmed">21613614</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai R, Cowan C, Heid B, Khan D, Liang Z, Pham CT, et al. . Neutrophils and neutrophil serine proteases are increased in the spleens of estrogen-treated C57bl/6 mice and several strains of spontaneous lupus-prone mice. PloS One (2017) 12(2):e0172105. doi:&#xa0;10.1371/journal.pone.0172105</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172105</ArticleId><ArticleId IdType="pmc">PMC5305105</ArticleId><ArticleId IdType="pubmed">28192517</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkmaz B, Caughey GH, Chapple I, Gauthier F, Hirschfeld J, Jenne DE, et al. . Therapeutic targeting of cathepsin c: from pathophysiology to treatment. Pharmacol Ther (2018) 190:202&#x2013;36. doi:&#xa0;10.1016/j.pharmthera.2018.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.05.011</ArticleId><ArticleId IdType="pubmed">29842917</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer R, Maenpaa J, Jauhiainen A, Larsson B, Mo J, Russell M, et al. . Dipeptidyl peptidase 1 inhibitor Azd7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther (2018) 104(6):1155&#x2013;64. doi:&#xa0;10.1002/cpt.1053</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1053</ArticleId><ArticleId IdType="pmc">PMC6282495</ArticleId><ArticleId IdType="pubmed">29484635</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk D, Janjic V, Stern I, Podobnik M, Lamba D, Dahl SW, et al. . Structure of human dipeptidyl peptidase I (Cathepsin c): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J (2001) 20(23):6570&#x2013;82. doi:&#xa0;10.1093/emboj/20.23.6570</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.23.6570</ArticleId><ArticleId IdType="pmc">PMC125750</ArticleId><ArticleId IdType="pubmed">11726493</ArticleId></ArticleIdList></Reference><Reference><Citation>Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 62(4):726&#x2013;59. doi:&#xa0;10.1124/pr.110.002733</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.110.002733</ArticleId><ArticleId IdType="pmc">PMC2993259</ArticleId><ArticleId IdType="pubmed">21079042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham CT. Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol (2008) 40(6-7):1317&#x2013;33. doi:&#xa0;10.1016/j.biocel.2007.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2007.11.008</ArticleId><ArticleId IdType="pmc">PMC2440796</ArticleId><ArticleId IdType="pubmed">18180196</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Ishikawa T, Lai Y, Nallapothula D, Singh RR. Diverse roles of netosis in the pathogenesis of lupus. Front Immunol (2022) 13:895216. doi:&#xa0;10.3389/fimmu.2022.895216</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.895216</ArticleId><ArticleId IdType="pmc">PMC9170953</ArticleId><ArticleId IdType="pubmed">35686129</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam LS, Rabelink TJ, van Kooten C, Teng YKO. Clinical implications of excessive neutrophil extracellular trap formation in renal autoimmune diseases. Kidney Int Rep (2019) 4(2):196&#x2013;211. doi:&#xa0;10.1016/j.ekir.2018.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2018.11.005</ArticleId><ArticleId IdType="pmc">PMC6365354</ArticleId><ArticleId IdType="pubmed">30775617</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanheira FVS, Kubes P. Neutrophils and nets in modulating acute and chronic inflammation. Blood (2019) 133(20):2178&#x2013;85. doi:&#xa0;10.1182/blood-2018-11-844530</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-844530</ArticleId><ArticleId IdType="pubmed">30898862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. . Phase 2 trial of the dpp-1 inhibitor brensocatib in bronchiectasis. N Engl J Med (2020) 383(22):2127&#x2013;37. doi:&#xa0;10.1056/NEJMoa2021713</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021713</ArticleId><ArticleId IdType="pubmed">32897034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Basso J, Lasala D, Fernandez C, Teper A, Zou J, et al. . Neutrophil serine protease levels in blood and sputum samples of patients on a reversible dipeptidyl peptidase 1 (Dpp1) inhibitor from the willow phase 2 trial in noncystic fibrosis bronchiectasis. In: Abstract retrieved from the 2nd European NTM &amp; bronchiectasis workshop (2021). EMBARC (The European Bronchiectasis Registry).</Citation></Reference><Reference><Citation>Cipolla D, Zhang J, Korkmaz B, Chalmers JD, Basso J, Lasala D, et al. . Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the willow trial. Respir Res (2023) 24(1):133. doi:&#xa0;10.1186/s12931-023-02444-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-023-02444-z</ArticleId><ArticleId IdType="pmc">PMC10189992</ArticleId><ArticleId IdType="pubmed">37198686</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon KB, Wiedeman A. Type I ifn system in the development and manifestations of sle. Curr Opin Rheumatol (2012) 24(5):499&#x2013;505. doi:&#xa0;10.1097/BOR.0b013e3283562c3e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e3283562c3e</ArticleId><ArticleId IdType="pubmed">22832823</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity (2006) 25(3):383&#x2013;92. doi:&#xa0;10.1016/j.immuni.2006.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.08.010</ArticleId><ArticleId IdType="pubmed">16979570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronnblom L, Leonard D. Interferon pathway in sle: one key to unlocking the mystery of the disease. Lupus Sci Med (2019) 6(1):e000270. doi:&#xa0;10.1136/lupus-2018-000270</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in sle pathogenesis and therapy. Nat Rev Rheumatol (2022) 18(10):575&#x2013;90. doi:&#xa0;10.1038/s41584-022-00826-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-022-00826-z</ArticleId><ArticleId IdType="pubmed">36097207</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Davidson A. Ifnalpha inducible models of murine sle. Front Immunol (2013) 4:306. doi:&#xa0;10.3389/fimmu.2013.00306</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00306</ArticleId><ArticleId IdType="pmc">PMC3788378</ArticleId><ArticleId IdType="pubmed">24106491</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, et al. . Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol (2009) 183(10):6831&#x2013;8. doi:&#xa0;10.4049/jimmunol.0900742</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900742</ArticleId><ArticleId IdType="pmc">PMC2876821</ArticleId><ArticleId IdType="pubmed">19864599</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore E, Putterman C. Are lupus animal models useful for understanding and developing new therapies for human sle? J Autoimmun (2020) 112:102490. doi:&#xa0;10.1016/j.jaut.2020.102490</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102490</ArticleId><ArticleId IdType="pmc">PMC7384952</ArticleId><ArticleId IdType="pubmed">32535128</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Bethunaickan R, Huang W, Lodhi U, Solano I, Madaio MP, et al. . Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum (2011) 63(1):219&#x2013;29. doi:&#xa0;10.1002/art.30087</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30087</ArticleId><ArticleId IdType="pmc">PMC3014995</ArticleId><ArticleId IdType="pubmed">20954185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. Ifn-alpha induces early lethal lupus in preautoimmune (New Zealand black X new Zealand white) F1 but not in Balb/C mice. J Immunol (2005) 174(5):2499&#x2013;506. doi:&#xa0;10.4049/jimmunol.174.5.2499</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.5.2499</ArticleId><ArticleId IdType="pubmed">15728455</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso J, Zhang J, Chen K-J, Zhou Y, Mark L, Dorfman A, et al. . Impact of Dpp1 inhibition on neutrophil serine proteases in na&#xef;ve rodent models. In: Abstract retrieved from international symposium neutrophil 2022. Mexico City, Mexico: NEUTROPHIL INTERNATIONAL SYMPOSIA; (2022).</Citation></Reference><Reference><Citation>Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19(1):71&#x2013;82. doi:&#xa0;10.1016/s1074-7613(03)00174-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1074-7613(03)00174-2</ArticleId><ArticleId IdType="pubmed">12871640</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PR, Brown GD, Geldhof AB, Martinez-Pomares L, Gordon S. Pattern recognition receptors and differentiation antigens define murine myeloid cell heterogeneity ex vivo. Eur J Immunol (2003) 33(8):2090&#x2013;7. doi:&#xa0;10.1002/eji.200324003</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200324003</ArticleId><ArticleId IdType="pubmed">12884282</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso J, Zhang J, Lasala D, Rose SJ, Chen KJ, Cipolla D. An optimized method of extracting and quantifying active neutrophil serine proteases from human whole blood cells. PloS One (2022) 17(8):e0272575. doi:&#xa0;10.1371/journal.pone.0272575</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272575</ArticleId><ArticleId IdType="pmc">PMC9432755</ArticleId><ArticleId IdType="pubmed">36044421</ArticleId></ArticleIdList></Reference><Reference><Citation>Helyer BJ, Howie JB. Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature (1963) 197:197. doi:&#xa0;10.1038/197197a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/197197a0</ArticleId><ArticleId IdType="pubmed">13953664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao S-Y, Xu Y, Zhang J, Schifferli K, An L-L, Leininger J, et al. . Antagonizing Hmgb1 inhibits proteinuria in a murine model of lupus-like disease (131.24). J Immunol (2007) 178(1_Supplement):S242&#x2013;S. doi:&#xa0;10.4049/jimmunol.178.Supp.131.24</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.Supp.131.24</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-Creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol (2004) 31(8):1557&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290735</ArticleId></ArticleIdList></Reference><Reference><Citation>Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest (2002) 109(3):363&#x2013;71. doi:&#xa0;10.1172/JCI13462</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI13462</ArticleId><ArticleId IdType="pmc">PMC150852</ArticleId><ArticleId IdType="pubmed">11827996</ArticleId></ArticleIdList></Reference><Reference><Citation>Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. . Efficacy and pharmacodynamic modeling of the btk inhibitor evobrutinib in autoimmune disease models. J Immunol (2019) 202(10):2888&#x2013;906. doi:&#xa0;10.4049/jimmunol.1800583</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800583</ArticleId><ArticleId IdType="pmc">PMC6500888</ArticleId><ArticleId IdType="pubmed">30988116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlach J, Bender AT, Przetak M, Pereira A, Deshpande A, Johnson TL, et al. . Discovery of M5049: a novel selective toll-like receptor 7/8 inhibitor for treatment of autoimmunity. J Pharmacol Exp Ther (2021) 376(3):397&#x2013;409. doi:&#xa0;10.1124/jpet.120.000275</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.120.000275</ArticleId><ArticleId IdType="pubmed">33328334</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-Severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther (2019) 13:1535&#x2013;43. doi:&#xa0;10.2147/DDDT.S170969</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S170969</ArticleId><ArticleId IdType="pmc">PMC6514126</ArticleId><ArticleId IdType="pubmed">31190735</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med (2020) 382(3):211&#x2013;21. doi:&#xa0;10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>
AstraZeneca . Saphnelo (Anifrolumab) approved in the us for moderate to severe systemic lupus erythematosus (2021). Available at: https://wwwastrazenecacom/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-slehtml#.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>